Skip to main content

Published locations for FDA grants priority review to polatuzumab vedotin for DLBCL

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA grants priority review to polatuzumab vedotin for DLBCL

User login

  • Reset your password
  • /content/fda-grants-priority-review-polatuzumab-vedotin-dlbcl
  • /hematologynews/article/194813/b-cell-lymphoma/fda-grants-priority-review-polatuzumab-vedotin-dlbcl
  • /oncologypractice/article/194813/b-cell-lymphoma/fda-grants-priority-review-polatuzumab-vedotin-dlbcl
  • /hematology-oncology/article/194813/b-cell-lymphoma/fda-grants-priority-review-polatuzumab-vedotin
  • /hematologytimes/article/194813/b-cell-lymphoma/fda-grants-priority-review-polatuzumab-vedotin-dlbcl
  • /b-cell-lymphoma-icymi/article/194813/b-cell-lymphoma/fda-grants-priority-review-polatuzumab-vedotin